These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 19071226

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 3. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T.
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD.
    Molimard M, Bourcereau J, Le Gros V, Bourdeix I.
    Respir Med; 2005 Jun; 99(6):695-702. PubMed ID: 15878485
    [Abstract] [Full Text] [Related]

  • 8. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM, Boulet LP, Follows RM.
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [Abstract] [Full Text] [Related]

  • 9. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease.
    Campbell M, Eliraz A, Johansson G, Tornling G, Nihlén U, Bengtsson T, Rabe KF.
    Respir Med; 2005 Dec; 99(12):1511-20. PubMed ID: 16199148
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C, Testi R, Polese G, Tosatto R, Rossi A.
    Pulm Pharmacol Ther; 2005 Dec; 18(2):103-8. PubMed ID: 15649852
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED, van Dyk M, Sagriotis A.
    Pulm Pharmacol Ther; 2008 Dec; 21(1):20-5. PubMed ID: 17118684
    [Abstract] [Full Text] [Related]

  • 17. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
    Rabe KF, Timmer W, Sagkriotis A, Viel K.
    Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
    [Abstract] [Full Text] [Related]

  • 18. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
    Bouros D, Kottakis J, Le Gros V, Overend T, Della Cioppa G, Siafakas N.
    Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Appleton S, Smith B, Veale A, Bara A.
    Cochrane Database Syst Rev; 2000 May; (2):CD001104. PubMed ID: 10796594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.